Title of Invention

PROCESS FOR THE PREPARATION OF SUBSTITUTED DIMETHYL-(3-ARYL-BUTYL)- AMINE COMPOUNDS BY MEANS OF HOMOGENEOUS CATALYSIS

Abstract

Compounds of the formula(II) can be hydrogenated to the corresponding butane derivatives in the presence of homogeneous catalysts comprising metal salts or complexes containing metals from the group consisting of Rh, Ir and Ru and preferably containing diphosphine ligands, with, in addition, excellent optical yields being achieved when one of R2 and R3 is not an H atom and the diphosphine ligand is chiral.

Full Text

Process for the preparation of substituted dimethyl-(3-arvl-butyl)-amine compounds by means of homogeneous catalysis The present invention relates to a process for the preparation of substituted dimethyl-(3-aryl- butyl)-amine compounds by means of homogeneous catalytic hydrogenation of dimethyl-(3- aryl-but-3-enyl)-amines. Dimethyl-(3-aryl-butyl)-amine compounds have proved to be pharmaceutical active compounds having an excellent analgesic activity and very good tolerability, see EP-A1- 0 693 475. WO 2005/000788 A1 describes a process for the preparation thereof, in which in a first stage substituted dimethyl-(3-aryl-but-3-enyl)-amine compounds are prepared by elimination of the tertiary hydroxyl group in substituted 4-dimethylamino-2-aryl-butan-2-ol compounds. These dimethyl-(3-aryl-but-3-enyl)-amine compounds are then hydrogenated in a second stage in the presence of metal catalysts. The heterogeneous hydrogenation proceeds in good yields with adequate activities. As expected, the stereoselectivity is not very pronounced. According to the examples in WO 2005/000788 A1, if two adjacent asymmetric C atoms are present diastereomeric ratios of from 2:1 to a maximum of 3:1 can be obtained for the trans diastereomer: cis diastereomer, that is to say always in favour of the trans diastereomer. The ratio is established automatically, essentially depends on the substrate and can be influenced by the choice of reaction conditions to only a small extent. The object of the present invention is to provide an improved and more flexible process for the preparation of substituted dimethyl-(3-aryl-butyl)-amine compounds. It has now been found that dimethyl-(3-aryl-but-3-enyl)-amine compounds can also be hydrogenated in a homogeneous phase in the presence of soluble hydrogenation catalysts, and high conversions and yields can be achieved by this procedure. It has furthermore been found that the stereoselectivity can be influenced in a targeted manner by the choice of chiral ligands, and very high optical yields can be achieved. It has also been found that the desired configuration can be obtained by the choice of ligands if the same substituted dimethyl-{3- aryl-but-3-enyl)-amine is used as the starting compound. The present invention provides a process for the preparation of a substituted dimethyl-(3- aryl-butyl)-amine compound of the general formula III wherein R1, R1', R2. R3 independently of one another each denote -H or -C1-5-alkyl, R4, R4, R5, R5', R6 are identical or different and each represent -H, -OH, -C1-4-alkyl, -O-C1-4- alkyl, partly fluorinated or perfluorinated -C1-4-alkyl, partly fluorinated or perfluorinated -O- C1-4-alkyl, -O-(CH2)n-pfienyl where n is 1, 2 or 3, F, CI or OR8, or two adjacent radicals R4 and R5, R5 and R6, R6 and R5' or Rs and R4' represent a group -OCH=CHO-, -CH=C(R9)-O-, -CH=C(R8)-S- or -CH=CH-C(OR10)=CH- as part of a ring, with the proviso that the other particular radicals R6, R5 and R4', R4, R5' and R6', R4, R5 and R4' or R4, R5 and R6 have the abovementioned meaning, Ra denotes -CO-C^-alkyl, -PO(0-C^-alkyl)2, -C0-C6H4-R11, -CO(O-C^-alkyl), -CO-CHR12- NHR13, -CO-NH-C phenyl group, R9 denotes -H or -Ci^-alkyl, R10 denotes -H or -C^-alkyl, R11 denotes -OCpj-C^-alkyl in the ortho-position or -CH2-N-{R15)2 in the meta- or para- position, wherein R15 in each case denotes -ClJt-alkyl or the two radicals R15 together with the bridging nitrogen atom form a 4-morpholino radical, R12 and R13 are identical or different and each represent -H, -Chalky! or -C^-cycloalkyl, or R12 and R13 together denote -(CH2)3-8 as part of a ring, R14 denotes -H, -OH, -C,.7-alkyl, partly fluorinated or perfluorinated -C^-alky!, -OCt-7-alkyl, -phenyl, -O-aryl, -F or -CI, with the proviso that the radicals R14 are identical or different, in each case in the form of one of their pure stereoisomers, in particular enantiomers or diastereomers, their racemates or in the form of a mixture of stereoisomers, in particular the enantiomers or diastereomers, in any desired mixing ratio, optionally in the form of a salt, a solvate or in the form of a salt and solvate, which is characterized in that a substituted dimethyl-(3-aryl-but-3-enyl)-amine compound of the general formula II wherein the radicals R1, R1', R2, R3, R4, R4, R5, R5' and R6 each have the abovementioned meaning, in each case in the form of racemates, pure enantiomers, mixtures of enantiomers in any desired mixing ratio, Z or E isomers or mixtures of Z or E isomers in any desired mixing ratio, salts or solvates, is reacted in the presence of hydrogen and a soluble metal salt or metal complex of metals from the group of iridium, rhodium and ruthenium, as a homogeneous catalyst, to give a compound of the general formula III. The process according to the invention is particularly suitable for asymmetric hydrogenations if the metal salts or metal complexes contain chiral ligands. Substituted dimethyl-(3-aryl-but-3-enyl)-amine compounds which are preferably used in the process according to the invention are those of the general formula IIA wherein R1 is -C^-alkyl, R2 denotes -H or -C^-alkyl, R3 denotes -H or -C^-alkyl, R4 is -H, -OH, -C14-alkyl, -O-CM-alkyl, -O-benzyl, -CF3, -O-CF3l -CI, -F or -OR8, R5 is -H, -OH, -C^-alkyl, -O-CM-alkyl, -O-benzyl, -CHF2, -CF3, -O-CF3, -CI, -F or -OR8, R6 denotes -H, -OH, -C14-alkyl, -O-Cu-alkyl, -O-benzyl, -CF3, -O-CF3, -CI, -F or -OR8, with the proviso that two of the radicals R4, R5 or R6 are -H, or R4 and R5 together denote a group -CH=C(R9)-O- or -CH=C(R9)-S- as part of a ring, wherein R6 is -H, or R5 and R6 together denote a group -CH=CH-C(OR10)=CH- as part of a ring, wherein R4 is -H, R8 denotes -CO-C^-alkyl, -PO(0-ClJralkyl)2, -CO-C6H4-R11, -CO(O-C^-alkyl), -CO-CHR12- NHR13, -CO-NH-C6H3-(R14)2 or an unsubstituted or substituted pyridyl, thienyl, thiazolyl or phenyl group, R9 denotes -H or-C^-alkyl, R10 denotes -H or C,.3-alkyl, R11 denotes -OC(0)-d.3-alkyl in the ortho-position or-CH2-N-(R15)2 in the meta- or para- position, wherein R15 is -C^-alkyl or the two radicals R15 together with the bridging nitrogen atom form a 4-morpholino radical, R12 and R13 are identical or different and each represent -H, -C^-alkyl or -C36-cycloalkyl, or R12 and R13 together denote -(CH2)3-s as part of a ring, Ru denotes -H, -OH, -d-r-alkyl, -O-Ci_7-alkyl, -phenyl, -O-aryl, -CF3, -CI or -F, with the proviso that the two radicals R14 are identical or different. Substituted dimethyl-(3-aryl-but-3-enyl)-amine compounds which are particularly preferably used in the process according to the invention are those of the general formula IIA in which R1 denotes -C^-alkyl, R2 denotes -H or C, j-alkyl, R3 denotes -H or Cw-alkyl, R4 denotes -H, -OH, -CI, -F or -OR8, R6 denotes -H, -OH, -C^-alkyl, -O-C^-alkyl, -O-benzyl, -CHF2, -CF3, -CI, -F or -OR8, R6 denotes -H, -OH, -O- C^-alkyl, -O-benzyl, -CF3, -CI, -F or -OR8, iiiisDiiiiiiaiR,i«-aiR,iRswi'»ea group -CH=C(R>0- or - a ring, with the proviso that K is -H, or H and R6 toaethor denotQ a croup -CH=CH-C(OR10)=CH- as part of a ring, with the proviso tha R4 is -li, and R8 to R10 have the abovementioned meaning. Substituted dimethyl-(3-aryl-but-3-enyl)-amine compounds which are very particularly preferably employed in the process according to the invention are those of the general formula IIA in which R1 is -CH3 or -C3H7, R2is-H,-CH3or-CH2CH3, R3is-H,-CH3or-CH2CH3, R4 is -H or -OH, R5 is -H, -OH, -OCH3, -CHF2 or -OR8, R6is-H,-OHor-CF3, with the proviso that two radicals R4, R5 or R6 are -H, or R* and R5 together represent a group -CH=C(CH3)-S- as part of a ring, wherein RB is -H, or R5 and R6 together denote - CH=CH-C(OH)=CH- as part of a ring, wherein R4 is -H, R8 denotes -CO-C6H4-R11 and R11 denotes -OC(0)-Ci.3-alkyl in the ortho-position. Substituted dimethyl-(3-aryl-but-3-enyl)-amine compounds which are very particularly preferably employed in the process according to the invention are those of the general formula IIA in which R1 and R3 each represent -CH3 and R5 represents -OCH3 and the other radicals represent a hydrogen atom, corresponding to the following formula MB, or the 2R enantiomer of the formula IIC The compound of the formula IIC, that is to say 3-[(3-methoxy-phenyl)-2-methyl-pent-3-enyl]- dimethylamine, in the form of its cis or trans isomer, namely (£)-(2R)-3-[(3-methoxy-phenyl)- 5-metnyl-penl-3-enyl]-Jimelnylamine according to the formula II0.2, and particularly preferably as (Z)-(2/?)-3-[(3-methoxy-phenyl)-2-methyl-pent-3-enyl]-dimethylamine according to the formula IIC. 1, or mixtures with a predominant content of the Z isomer, is most preferably employed. Starting from mixtures, but preferably from one of the isolated enantiomers, the largely stereoselective preparation of one of the two diastereomers of the formulae III.C1 or III.C2 is possible with the process according to the invention with the choice of appropriately suitable chiral ligands for the homogeneous catalyst: Therefore, in the process according to the invention (Z)-(2R)-3-[(3-methoxy-phenyl)-2-methyl-pent-3-enyl]-dimethylamine according to the formula IIB.1 is preferably employed, and predominantly the diastereomer (2R, 3/?)-[3-(3-methoxy-phenyl)-2-methyl-pentyl]-dimethyl- amine of the formula IIIB.1 is preferably prepared. The former means that the mixture of the precursors is worked up in accordance with methods known to the person skilled in the art - described briefly in the following - in order to provide the 2 isomer for the hydrogenaiion. The latter means that by appropriate choice of the chiral catalyst, predominantly the diastereomer (2R, 3R)-[3-(3-methoxy-phenyl)-2-methyl-pentyl]-dimethyl-amine, that is to say the trans form, is obtained. A high degree of stereoselectivity can be defined as meaning that the hydrogenation gives a product with an enantiomeric excess (abbreviated to "ee") or diastereomeric ratio (abbreviated to "d.r."). The enantiomeric excess is defined as the ratio (% R - % S) / (% R + % S), wherein % R represents the percentage content of the R form and % S represents the percentage content of the S form on a chirality centre. Since the compounds of the formulae IIB.1 and IIB.2 have the R form on the C2 atoms, after the hydrogenation the now chiral centre on the C3 atom can be present either likewise in the R or S form. Two diastereomers can therefore be present, namely the (2R, 3R) or trans form and the [2R, 3S) or cis form. The trans or cis form is as a rule referred to in the following for simplification, the particular diastereomers previously referred to then being meant. With the process according to the invention, the hydrogenation can be carried out starting from a mixture of compounds of the formulae IIC.1 and IIC.2, and nevertheless a diastereomeric excess of either the trans or the cis form is obtained. For process optimization reasons, however, it is advantageous to use either the isolated Z or the isolated E isomer as the starting substance, since isolation of one of the isomers additionally renders possible the removal of by-products. In the context of the present invention, the Z isomer is preferably used as the starting educt. By choice of an appropriate catalyst, starting from the Z isomer a ratio optionally selectively in favour of the cis or of the trans form of the product can be achieved. In this context, a ratio of greater than or equal to 70:30, preferably greater than or equal to 75: 25, particularly Bffiffiri&lY tiff 8lf r tfP ?F eWa' *° 8°; 20. especially preferably greater than or equal to 85 : 15, very particularly preferably greater than or equal to 90:10, in favour of the desired cis or trans form is defined as good selectivity. The starting compounds for the process according to the invention in the form of the .JlJlJIittlw and lie can be obtained e.g. by dehydration from substituted 4-dimethylamino-2-aryl-t?utan- 2-ol compounds of the general formula I If the substituted dimethyl-(3-aryl-but-3-enyl)-amine compounds of the general formulae II, HA, MB and IIC or the substituted dimethyl-(3-aryl-butyl)-amine compounds of the general formula III are obtained in the form of their bases by the process according to the invention, they can be converted into the corresponding salts, preferably into one of the salts listed above, by conventional processes known to the person skilled in the art. Metal complexes of rhodium, iridium and ruthenium, preferably of rhodium and iridium, in particular of rhodium, with diphosphine ligands are particularly suitable for the process according to the invention of hydrogenation of the compounds of the general formulae 11,1IA, IIB and IIC described above with hydrogen by means of homogeneous catalysis. Little is known of the homogeneous catalysis of homo-allylic amines of the general formula II. It is all the more surprising that excellent conversions and yields and very high optical yields of desired stereoisomers can be achieved, in particular when rhodium complexes are used. It may be advantageous to start from stereochemical^ pure educts of high chemical purity for this. However, mixtures which have not been worked up and in which Z and £ isomers equally exist can optionally also be employed. Possible diphosphine ligands are, for example, diphosphines and analogues such as are to be found, for example, in current overviews, inter alia in a) H. Brunner, W. Zettlmeier, Handbook of Enantioselective Catalysis. VCH Weinheim, 1993, vol. 2, page 3 et seq.; b) R. Noyori, et al. in Catalytic Asymmetric Synthesis Second Edition (I. Ojima, "a), Wiley- YCtl, YYSinheim, 200g, Rip 1 ft §eq,; 9) E.N. Jacobsen, A. Pfaltz, H. Yamamoto (Eds.), Comprehensive Asymmetric datalysis vol. /-///, springer Berlin, 1555, ana references cited therein. Achiral and chiral structures of the secondary phosphine-skeleton-secondary phosphine type are generally possible. TK4 rilo secoAclty phoiP^S SWUfl BP& PfefefSoly M tO 0 §m sued tit tog&tnm m metal atom, 0 y to iwrara, and more prctcraDiy 5- to 8-membered ring is formed in the metal complex. The two secondary phosphine groups are bonded terminally to the C atoms of a C2-C8-, preferably C2-C6- and particularly preferably C2-C4-chain, wherein C atoms of the chain can be replaced by hetero atoms 0, S, NH and/or N-C,-C4-alkyl and the carbon chain can be part of a monocyclic or polycyclic ring. Trio ctelQton can contain 2 to 30, preferably two to 20 C atoms and optionally additionally 1 to 4 hetero atoms. The skeleton can be unsubstituted or substituted, for example by Ci-CB- alkyl, Cfl-Ce-alkoxy, CVCValkylthio, C4-C8-cycloalkyl, phenyl, benzyl, phenoxy, benzyloxy, phenylthio, benzylthio, halogen (preferably F, CI, Br), OH, tr^CrCe-alkylJsilyl, secondary amino, -C02H, -S03H, -C02R'. -S03R', -O-C(0)-R', -NH-C(0)R', -O-SO3-R', and -NH-SO3R', wherein R' represents C^Ce-alkyl, C4-CB-cycloalkyl, phenyl or benzyl. The skeleton can be bivalent radicals of alkanes, heteroalkanes, alkenes, cycloalkanes, cycloalkenes, heterocycloalkanes, heterocycloalkenes, bicycloalkanes, bicycloheteroalkanes, spirobiscycloalkanes, spirobiscycloheteroalkanes, arylenes, heteroarylenes, bisarylenes, bisheteroarylenes, metallocenes, such as, for example, ferrocenes, wherein one or both phosphine groups can be bonded to the cyclopentadienyl ring of a metallocene via a methylene, Ci-C^-alkylidene, phenylene or -CR"R*-phenylene. R" and R* independently of one another are, for example, CVCValkyl, (VCValkoxy or phenyl. The free bonds are on one or both cyclopentadienyl rings. In the cyclic skeletons, the free bonds are preferably in 1,2- positions and in 1,1-bisaryls in the 6,6'-position. The secondary phosphine groups can also be bonded to C atoms of the skeleton via an oxygen atom (these are then phosphinites). The chirality of the diphosphine ligands can be based on planar isomerism (ferrocenes), atropisomerism, the presence of asymmetric C atoms and/or P atoms or combinations thereof, Examples of skeletons of atropisomers are 1,1'-bisaryls and -bisheteroaryls (bisaryls such as, for example, biphenyl, binaphthyl or bisthiophenyl) with secondary phosphine groups b'nWink¥T*frt»«!iffiiifliiniifi!riiii awiiSJ[iPisio[siiisiiiJiiaiep3ffl»te. Bicyclopentanes, which are commercially obtainable under the trivial name Bicp, are also known as the base skeleton. Examples of skeletons having planar chirality are those based on ferrocenes with two secondary phosphine groups bonded directly to in each case one of the cyclopentadienyl rings or bonded to a GyGlopentadienyl ring in trio 1,2-position and optionally Glial substituents on one or both cyclopentadienyl rings. Another example are ferrocenes to which a secondary phosphine group is bonded in the 1,2-position of the cyclopentadienyl ring and a further secondary phosphine group is bonded via an asymmetric C atom. A further example are ferrocenes to which a secondary phosphine group is bonded in the 1,2-position of the cyclopentadienyl ring via an asymmetric C atom and a second secondary phosphine group is bonded via 1,2-phenylene. Trivial names for such ligands are Josiphos, Walphos, Taniaphos, Mandyphos and Ferriphos. Diphosphines having chiral P rings which are substituted in particular in one or both a- positions to the P atom, for example phospholanes and phosphetanes, are also known. Such secondary phosphine groups can be bonded in the 1,2-position of benzene, naphthalene, thiophene, benzothiophene, ethane and ferrocene. Known trivial names are Rophos, Butiphane and Kephos. Examples of skeletons having asymmetric C atoms are open-chain with in the 1,2-, 1,3- or 1,4-positions, aliphatic bicyclic ring systems with secondary phosphine groups bonded in the 1,2-positions, or cyclic or heterocyclic five-membered rings with secondary phosphine groups bonded in the 3,4-positions, optionally via a methylene group. Five-membered rings with a secondary phosphine group bonded in the 4-position and a secondary phosphinemethyl group bonded in the 2-position are also known. Trivial names for such ligands are Diop, Bppm, Bzppm, Depyphos, Norphos and Prophos. Examples of diphosphines having chiral P atoms are 1,2-bis(secondary phosphine)ethanes with different substituents in the phosphine groups. A known representative is obtainable undor trio trivial name Dipamp. The secondary phosphine groups can contain identical or different hydrocarbon radicals as substituents, and the two secondary phosphine groups in the diphosphines can be identical or different. Good results can often be achieved if the secondary phosphine groups are not identical but are different. The hydrocarbon radicals can be unsubstituted or substituted and/or can contain hetero atoms chosen from the group 0, S, -N= or N(CrC4-alkyl). They can contain 1 to 22, preferably 1 to 12 and particularly preferably 1 to 8 C atoms. A preferred secondary phosphine is that wherein the phosphine group contains two identical or different radicals chosen from the group of linear or branched CrCi2-alkyl; C5-Ci2- cycloalkyl or C6-C12-cycloalkyl-CH2- which is unsubstituted or substituted by CrC6-alkyl or CrC6-alkoxy; phenyl, naphthyl, furyl or benzyl; or phenyl or benzyl which is substituted by halogen, d-Ce-alkyl, trifluoromethyl, d-C6-alkoxy, trifluoromethoxy, (C6H6)3Si, (C,-C12- alkyl)3Si or secondary amino. Examples of substituents on P as alkyl which preferably contains 1 to 6 C atoms are methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, t-butyl and the isomers of pentyl and hexyl. Examples of substituents on P as cycloalkyl optionally substituted by alkyl are cyclopentyl, cyclohexyl, methyl- and ethylcyclohexyl and dimethylcyclohexyl. Examples of substituents on P as phenyl and benzyl substituted by alkyl and alkoxy are methylphenyl, dimethylphenyl, trimethylphenyl, ethylphenyl, methylbenzyl, methoxyphenyl, dimethoxyphenyl, trimethoxyphenyl, trifluoromethylphenyl, bis-trifluoromethylphenyl, tris-trifluoromethylphenyl, trifluoromethoxyphenyl, bis-trifluoromethoxyphenyl, fluoro- and chlorophenyl and 3,5- dimethyl-4-methoxyphenyl. Preferred secondary phosphine groups are those which identical or different radicals chosen from the group of CrC6-alkyl, or cyclopentyl or cyclohexyl which is unsubstituted or substituted by 1 to 3 CrC4-alkyl or d-C4-alkoxy, or benzyl and in particular phenyl, which are unsubstituted or substituted by 1 to 3 Ci-C4-alkyl, Ci-C4-alkoxy, C1-C4-fluoroalkyl or d-C4- fluoroalkoxy, F and CI. ThQ CQCOndgry Ph08phin0 grOUP preferably corresponds to the formula -PR18R17, wherein R16 and R17 independently of one another represent a hydrocarbon radical having 1 to 18 C atoms, WhiCh i2 UnSUbStitUted 6r substituted by CrC6-alkyl, trifluoromethyl, C,-C6-alkoxy, trifluoromethoxy, (CrC4-aikyl)^immo, (C6H5)3Si, (C1-C12-alkyl)3Si, halogen, and/or contains hetero atoms 0. R16 and R17 are preferably radicals chosen from the group of linear or branched d-CB-alkyl, or cyclopentyl or cyclohexyl which is unsubstituted or substituted by one to three d-C-alkyl or d-C4-alkoxy, furyl, benzyl which is unsubstituted or substituted by one to three CrC4-alkyl or Ci-Cd-alkoxy and in particular phenyl which is unsubstituted or substituted by one to three F, CI, Ci-C4-alkyl, Ci-C4-alkoxy, CrC4-fluoroalkyl or CrC4-fluoroalkoxy. R16 and R17 particularly preferably denote radicals chosen from the group of d-C6-alkyl, cyclopentyl, cyclohexyl, furyl, and phenyl which is unsubstituted or substituted by one to three F, CI, C,-C4-alkyl, CrC4-alkoxy and/or d-C4-fluoroalkyl. If R16 and R17 in the group -PR16Ri7 are different, ligands which are additionally chiral on the P are present. The secondary phosphine group can be cyclic secondary phosphino, for example those of the formulae which are unsubstituted or substituted once or several times by Ci-Ce-alkyl, C4-C8-cycloalkyl, d-Ce-alkoxy, C,-C4-alkoxy-Ci-C4-alkyl, phenyl, C|-C4-alkyl- or C1-C4-alkoxyphenyl, benzyl, CrC4-alkyl- or d-Cralkoxybenzyl, benzyloxy, CrC4-alkyl- or (Vd-alkoxybenzyloxy, or d- C4-alkylidene-dioxyl. The substituents can be bonded in one or both ^-positions to the P atom, in order to introduce chiral C atoms. The substituents in one or both a-positions are preferably C1-C4- alkyl or benzyl, for example methyl, ethyl, n- or i-propyl, benzyl or -CH2-O-CrC4-alkyl or -CH2-O-C6-Cio-aryl. Substituents in the/?,K-positions can be, for example, Ci-C4-alkyl, d-d-alkoxy, benzyloxy, or -O-CHz-O-, -O-CH(CrC4-alkyl)-O-, and -O-Ctd-CValkylk-O-. Some examples are methyl, ethyl, methoxy, ethoxy, -O-CH(methyl)-O-, and -O-C(methyl)2-O-. DQpendiflQ On the natUPfi Of the 5Ub5titUehts and the number of substituents, the cyclic phosphine radicals can be chiral on the C, chiral on the P or chiral on the C and P. An aliphatic 5- or 6-membered ring or benzene can be fused on to two adjacent C atoms in the radicals of the above formulae. The cyclic secondary phosphino can correspond, for example, to the following formulae (only one of the possible diastereomers is shown) wherein the radicals R' and R" represent CrC4-alkyl, for example methyl, ethyl, n- or i-propyl, benzyl, or -CH2-O-CrC4-alkyl or -CH2-O-C6-C10-aryl, and R' and R" are identical or different from one another. The two secondary phosphino radicals -PR16R17 in diphosphines preferably independently of one anotfiof flenoiG [icmiifdicactionflaf} pluspiiinc onoscn fromitic group olfjOi-Oj-i^, -P(C5-C8-cycloalkyl)2, -P(CrC8-bicycloalkyl)2, -P(o-furyl)2, -P(C6H5)2, -Pp-fA-Ce-alkyDCsHJs, mu-Ami, mujML muj™M> wiu- alkoxy)C6H4]2, -P^Ct-Qs-alkoxyJCeHJa, -P[2-(trifluoromethyl)C6H4]2) -P[3- (trifluoromethyl)C6H4]2,-P[4-(trifluoromethyl)C6H4]2,-P[3,5-bis(trifluoromethyl)C6H3]2,-P[3,5- bis(C1-C6-alkyl)2C6H3]2,-P[3,5-bis(C1-C6-alkoxy)2C6H3]2,and-P[3,5-bis(C1-C6-alkyl)2-4-(C1-C6- alko>c/)C6HJ2, or cyclic phogphine chosen from the group of which are unsubstituted or substituted once or several times by C,-C4-alkyl, (VCValkoxy, Cr C4-alkoxy-CrC2-alkyl, phenyl, benzyl, benzyloxy, or C^Qi-alkylidene-dioxyl. Some specific examples are -P(CH3)2, -P(i-C3H7)2, -P(n-C4H9)2, -P(i-C4H9)2, -P(t-C4H9)2, -P(C5H9), -P(C6H„)2, -P(norbornyl)2, -P(o-furyl)2, -P(C6H5)2, P[2-(methyl)C6H4]2, P[3- (methyl)C6H4]2, -P[4-(methyl)C6H4]2, -P[2-(methoxy)C6H4]2, -P[3-(methoxy)C6H4]2, -P[4- (methoxy)C6H4]2, -Pt3-(trifluoromethyl)C6H4]2, -P[4-(trifluoromethyl)C6H4]2, -P[3,5- bis(trifluoromethyl)C6H3]2, -P[3,5-bis(methyl)2C6H3]2, -P[3,5-bis(methoxy)2C6H3]2, and -P[3,5- bis(methyl)2-4-(methoxy)C6H2]2, and those of the formulae wherein R' represents methyl, ethyl, methoxy, ethoxy, phenoxy, benzyloxy, methoxymethyl, ethoxymethyl or benzyloxymethyl and R" independently has the same meaning as R'. Preferred diphosphine ligands are chosen from those of the formulae: (A) Ligands of the general formula : (B) Ligands of the general formula: (C) Ligands of the general formula: (D-G) Ligands of the general formulae: In the ligands of the general formulae A to G, X^ and X2 denote P-bonded secondary phosphine groups, including the embodiments and preferred meanings. A very particularly preferred ligand of the general formula A contains as the radical XT and X2 in each case an unsubstituted diphenylphosphine group. A very particularly preferred ligand of the general formula B contains as the radical X-, a di(2- furyl)phosphine group, as the radical X2 a dixylylphosphine group, and as the radical R a methyl group. A very particularly preferred ligand of the general formula C contains as the radical X-, a dixylylphosphine group, as the radical X2 likewise a dixylylphosphine group, and as the radical R a methyl group. Very particularly preferred ligands of the general formulae D, F and G contain as the radical X! and X2 in each case an unsubstituted diphenylphosphine group. A very particularly preferred ligand of the general formula E contains as the radical X, a dixylylphosphine group, and as the radical X2 a dicyclohexylphosphine group. R in the general formulae B and C represents the possible radicals C1-C4-alkyl, preferably methyl, C6-C10-aryl, preferably phenyl, or C7-C12-aralkyl, preferably benzyl. Ligands which are furthermore preferred are those of the general formulae H and I: wherein X-, and X4 independently of one another denote H, OH, d-C^alKyl, d-CralkOXy, rMy My. -TOrUU- or -L^Uenyly, preferably in each case -OH. Finally, preferred diphosphine ligands are generally those with which a diastereomeric ratio in favour of either the trans or the cis form of greater than or equal to 70: 30, preferably greater than or equal to 75 : 25, particularly preferably greater than or equal to 80: 20, op!! protein greater in or epi to 03:11 wa partiofirn pnfir an oroir ra or equal to 90 :10 can be achieved. Very particularly preferred embodiments of the process according to the invention are: a) Process, characterized in that a compound of the formula IIC.1 A,MeU (IV), (A,MeL„)(2t)(E-)z (V), wherein A, represents a diphosphine ligand, including the embodiments and preferred meanings, in particular of the formulae A to I, L represents identical or different monodentate, anionic or nonionic ligands, or two L represent identical or different bidentate, anionic or nonionic ligands; n represents 2, 3 or 4 if L denotes a monodentate ligand, or n represents 1 or 2 if L denotes a bidentate ligand; z represents 1,2 or 3; Me = rhodium (Rh), iridium (Ir) and ruthenium (Ru), preferably Rh and Ir, in particular Rh; wherein the metal has the oxidation levels 0,1, 2, 3 or 4; E" is the anion of a oxygen acid or complex acid; and the anionic ligands compensate the charge of the oxidation levels 1, 2, 3 or 4 of the metal. Monodentate nonionic ligands can be chosen, for example, from the group of olefins (for example ethylene, propylene), allyls (allyl, 2-methallyl, solvating solvents (nitriles, linear or cyclic ethers, optionally N-alkylated amides and lactams, amines, phosphines, alcohols, carboxylic acid esters, sulfonic acid esters), nitrogen monoxide and carbon monoxide, Monodentate anionic ligands can be chosen, for example, from the group of halide (F, CI, Br, I), pseudohalide (cyanide, cyanate, isocyanate) and anions of carboxylic acids, sulfonic acids and pnospnonic acids (carbonate, formate, acetate, propionate, metnylsuliulnate, trifluoromethylsulfonate, phenylsulfonate, tosylate). Bidentate nonionic ligands can be chosen, for example, from the group of linear or cyclic diolefins (for example hexadiene, cyclooctadiene, norbornadiene), dinitriles (malonodinitrile), orally \n\\\]\m mm)\\t m diamiyesi diamine dipiMptiesi Mis, acetonylacetonates, dicarboxylic acid diesters and disulfonic acid diesters. Bidentate anionic ligands can be chosen, for example, from the group of anions of dicarboxylic acids, disulfonic acids and diphosphonic acids (for example of oxalic acid, malonic acid, succinic acid, maleic acid, methylenedisulfonic acid and methylenediphosphonic acid). Preferred metal complexes are also those wherein E represents -Cr, -Br, -l\ CI04~, CF3SCy, CH3S03-, HS04", BF4~, B(phenyl)4", B(C6F5)4~, B(3,5-bistrifluoromethyl-phenyl)4*, PF6", SbCI6 , AsF6" or SbF6Particularly preferred metal complexes correspond to the formulae VI and VII [A,Me,YZ] (VI), [A^YTEr (VII), wherein At represents a diphosphine ligand, including the embodiments and preferred meanings, in particular of the formulae A to I; Mei denotes rhodium (Rh) and iridium (Ir), in particular Rh; Y represents two olefins or a diene; Z denotes CI, Br or I; and Er represents the anion of an oxygen acid or complex acid. Y in the meaning as olefin can be C2-Cir, preferably C2-C6- and particularly preferably C2-C4- olefins. Examples are propene, but-1-ene and, in particular, ethylene. The diene can contain 5 to 12, and preferably 5 to 8 C atoms, and it can also be open-chain, cyclic or polycyclic dienes. The two olefin groups of the diene are preferably joined by one or two CH2 groups. Examples are 1,3-pentadiene, cyclopentadiene, 1,5-hexadiene, 1,4-cyclohexadiene, 1,4- or 1,5-heptadiene, 1,4- or 1,5-cycloheptadiene, 1,4- or 1,5-octadiene, 1,4- or 1,5-cyclooctadiene and norbornadiene. Preferably, Y represents two ethylene or 1,5-hexadiene, 1,5-cyclooctadiene or norbornadiene. In formula VI, Z preferably represents CI or Br. Examples of E^ are CI04", CF3S03", CH3SO3', HS04\ BF4", B(phenyl)4\ PF6\ SbClg", AsF6" or SbF6Ruthenium complexes can correspond, for example, to the formula VIII [Ru.HbZc(A1)dLJKEkWS)h (VIII), wherein Z denotes CI, Br or I; Ai represents a compound of the formulae I or la; L represents identical or different ligands; E" is the anion of an oxygen acid, mineral acid or complex acid; S represents a solvent, as a ligand, which is capable of coordination; and a denotes 1 to 3, b denotes 0 to 4, c denotes 0 to 6, d denotes 1 to 3, e denotes 0 to 4, f denotes 1 to 3, g denotes 1 to 4, h denotes 0 to 6 and k denotes 1 to 4, wherein the total charge of the complex is neutral. The preferred meanings of Z, A-,, L and E" described above apply to the compounds of the formula VIII. The ligands I can additionally be arenes or heteroarenes (for example benzene, naphthalene, methylbenzene, xylene, cumene, 1,3,5-mesitylene, pyridine, biphenyl, pyrrole, benzimidazole or cyclopentadienyl) and metal salts having a Lewis acid function (for example ZnCI2, AICl3, TiCI4 and SnCI4). The solvent ligands can be, for example, alcohols, amines, acid amides, lactams and sulfones. Complexes of this type are described in the literature mentioned in the following and in the literature cited therein: D. J. Ager, S. A. Laneman, Tetrahedron: Asymmetry, 8, 7997, 3327 - 3355; T. Ohkuma, R. Noyori in Comprehensive Asymmetric Catalysis (E.N. Jacobsen, A. Pfaltz, H. Yamamoto, Eds.), Springer, Berlin, 1999, 199-246; J. M. Brown in Comprehensive Asymmetric Catalysis (E.N. Jacobsen, A. Pfaltz, H. Yama- moto, Eds.), Springer, Berlin, 1999,122-182; T. Ohkuma, M. Kitamura, R. Noyori in Catalytic Asymmetric Synthesis, 2nd Edition (I. Ojima, Ed.), Wiley-VCH New York, 2000,1-110; N. Zanetti, etal. Organometallics 15,1996, 860. The metal complexes are prepared by methods known in the literature (see e.g. Comprehensive Asymmetric Catalysis I bis III, Springer Verlag, Berlin, 1999, and literature cited therein). The process according to the invention can be carried out in accordance with the usual conditions from the prior art with respect to the process parameters for the hydrogenation, that is to say under the conditions with respect to pressure, temperature, solvents and amounts. The most important parameters are summarized as follows: The process according to the invention can be carried out at low or elevated temperatures, for example temperatures of from -20 to 150 °C, preferably from -10 to 100 °C, and particularly preferably from 10 to 80 °C. The optical yields are in general better at lower temperature that at higher temperatures. The process according to the invention can be carried out under normal pressure or increased pressure. The pressure can be, for example, from 105 to 2x107 Pa (Pascal). Hydrogenations are preferably carried out under increased pressure. Catalysts are preferably used in amounts of from 0.00001 to 10 mol%, particularly preferably 0.0001 to 5 mol%, and especially preferably 0.001 to 2 mol%, based on the compound to be hydrogenated. The preparation of the ligands and catalysts and the hydrogenation can be carried out without or in the presence of an inert solvent, it being possible to employ one solvent or mixtures of solvents. Suitable solvents are, for example, aliphatic, cycloaliphatic and aromatic hydrocarbons (pentane, hexane, petroleum ether, cyclohexane, methylcyclohexane, benzene, toluene, xylene), aliphatic halohydrocarbons (methylene chloride, chloroform, di- and tetrachloroethane), nitriles (acetonitrile, propionitrile, benzonitrile), ethers (diethyl ether, dibutyl ether, t-butyl methyl ether, ethylene glycol dimethyl ether, ethylene glycol diethyl ether, diethylene glycol dimethyl ether, tetrahydrofuran, dioxane, diethylene glycol monomethyl or monoethyl ether), ketones (acetone, methyl isobutyl ketone), carboxylic acid esters and lactones (ethyl or methyl acetate, valerolactone), N-substituted lactams (N-methylpyrrolidone), carboxylic acid amides (dimethylacetamide, aimetnylrormamide), acyclic ureas (dimetnylimidazoline), ana sulfoxides ana suliones (dimethylsulfoxide, dimethyl sulfone, tetramethylene sulfoxide, tetramethylene sulfone) and alcohols (methanol, ethanol, propanol, butanol, ethylene glycol monomethyl ether, ethylene glycol monoethyl ether, diethylene glycol monomethyl ether, trifluoroethanol) and water. The solvents can be used by themselves or in a mixture of at least two solvents. It may be advantageous to carry out the reaction in the presence of metal or ammonium halides which are soluble in the reaction mixture, for example alkali metal chlorides, bromides and iodides, or quaternary ammonium halides, such as, for example, tetrabutylammonium iodide. It may be particularly expedient, for example if the substrate is employed as a free base, to carry out the hydrogenation in the presence of acids, for example organic acids, such as sulfonic acids (methanesulfonic acid, trifluoromethanesulfonic acid), carboxylic acids (formic acid, acetic acid, oxalic acid), phosphonic acids (meihanephospKonic acid), mineral acids, such as hydrogen halide acids (HCI, HBr, HI), sulfuric acid, phosphorous acid, phosphoric acid (see, for example, US-A-5,371,256, US-A-5,446,844 and US-A-5,583,241 and EP-A-0 691 949). The acid can be chosen such that a desired salt of the active compound is obtained directly. The amount of acid can accordingly be up to 1 equivalent or more, for example an excess of up to 1.5 equivalents, based on the amount of substrate to be hydrogenated. A suitable range of amounts is 0.01 to 1 equivalent of acid, based on the amount of substrate to be hydrogenated. The metal complexes used as catalysts can be added as separately prepared, isolated compounds, or can preferably also be formed in situ before the reaction and then mixed with the substrate to be hydrogenated. It may be advantageous additionally to add ligands in the reaction using isolated metal complexes, or to employ an excess of the ligands in the in situ preparation. The excess can be, for example, 1 to 10, and preferably 1 to 5 mol per cent, based on the metal compound used for the preparation. The process according to the invention is in general carried out by a procedure in which the catalyst is initially introduced into the reaction vessel and the substrate, optionally reaction auxiliaries and the gaseous compound to be added on, in the form of hydrogen, are preferably forced in. The process can be carried out continuously or batchwjse jn various types of reactor. The chiral organic compounds which can be prepared according to the invention are active substance or intermediate products for the preparation of such substances, in particular in the field of preparation of pharmaceuticals. Gas chromatography (GO determinations are carried out as follows: a) Sample preparation: tert-Butyl methyl ether is added to the sample material. Hydrochlorides are liberated with Dowex MWA-1 to give the base. The clear organic phase is injected. p) Gas chromatography conditions: Capillary column: 6 % cyanopropyl-phenyl, 94 % dimethylpolysiloxane, e.g. Optima 1301-DF 30 m x 0.32 mm, 1.0 /;m film thickness; carrier gas: helium; pre-pressure: 70 kPa; split: 20 ml/min; oven temperature programme: initial 160 °C/5 min, rate 5 °C/min, 190 °C/9 min, rate 10 °C/min; 250 °C/14 min; detector temperature: FID/260 °C A) Preparation of starting compounds [compounds of the general formula (11)1: Example A1: (Z,EH2R)-f3-(3-Methoxv-phenvl)-2-methvl-pent-3-envl]-dimethvl-amine 28.7g (0.1 mol) of (2S,3R)-1-dimethylamino-3-(3-methoxy-phenyl)-2-methyl-pentan-3-ol hydrochloride are initially introduced into a 250 ml three-necked flask with a thermometer, mechanical compressed air stirrer, reflux condenser and oil bath heating and 150 ml of aqueous 36 wt.% strength hydrochloric acid are added. The mixture is heated to 100 °C for 1 h. It is cooled to 20 °C and adjusted to a pH of 11 with 33 wt.% strength sodium hydroxide solution at 20 °C, while cooling. 150 ml of ethyl acetate are added, the mixture is stirred for 10 min, the stirrer is switched off, the phases are separated and the ethyl acetate is distilled off on a rotary evaporator at 60 °C down to a pressure of 10 mbar. The oily residue consists of (Z,£)-(2/?)-[3-(3-methoxy-phenyl)-2-methyl-pent-3-enyl]-dimethyl-amine with a GC purity of 86 %, a 7JE ratio of 6.5:1 and a yleld of 21 g (90 % of theory). In the purity analysis, no starting product and 8.5 % of (Z,E)-[3-(3-methoxy-phenyl)-2-methyl-pent-2-enyl]-dirnethyl- amine was found. Example A2: (ZV(2R)-r3-(3-Methoxy-phenvl)-2-methyl-pent-3-envll-dimethvl-amine 201 g (0.86 mol) of a mixture of (Z)-(2/?)-[3-(3-methoxy-phenyl)-2-methyl-pent-3-enyl]- dimethyl-amine, (£)-(2R)-[3-(3-methoxy-phenyl)-2-methyl-pent-3-enyl]-dimethyl-amineand HIIREiailBniMllMll^lUI^U are added. 94.0 g (0.87 mol) of trimethylcfilorosilane are then added dropwise and the mixture is stirred at 5 °C - 8 °C for 72 h. The crystals which have precipitated out are filtered Off With 5UCfiW\ 5uu \W& With aCetonfe. The product is then dried in a drylng cabinet under 80-120 mbar at 40 - 50 °C. The (Z)-(2R)-[3-(3-methoxy-phenyl)-2-methyl-pent-3-enyl]-dime- thvl-amine hydrochloride crude product obtained is dissolved in 513 ml of water and the solution is adjusted to a pH of 11-12 with sodium hydroxide solution. 500 ml of ethyl acetate are added to the aqueous solution and the product is extracted. The ethyl ester phase which has been separated off is dried over sodium sulfate and concentrated on a rotary evaporator. The (Z)-(2R)-[3-(3-methoxy-phenyl)-2-methyl-pent-3-enyl]-dimethyl-amine obtained in this way is dissolved in 733 ml of acetone and 11.2 g (0.63 mol) of water are added. 67.8 g (0.63 mol) of trimethylchlorosilane are slowly added. The reaction mixture is stirred at 5-8 °C for 72 hours. The solid which has precipitated out is then filtered off with suction and rinsed with acetone. The product is dried in a drylng cabinet under 80-120 mbar at 45-50 °C for 16 hours. The yleld is 134.4 g (58 %) with a purity of 100.0 %. The ratio of Z to E isomer is 99.05 : 0,95. B) Hydrogenations (preparation of the two diastereomers (2R, 3/?)-[3-(3-methoxy-phenyl)-2- methyl-pentyl]-dimethyl-amine and (2R, 3S)-[3-(3-methoxy-phenyl)-2-methyl-pentyl]- dimethyl-amine) Example B1: General process for the catalytic hydroqenation: An autoclave is filled with argon under an applied pressure of 10-12 bar and is discharged again. This operation is carried out four times. 0.5 g (2.14 mmol) of the (Z)-(2/?)-[3-(3- methoxy-phenyl)-2-methyl-pent-3-enyl]-dimethyl-arnine obtained according to Example A.2 and 5 ml of freshly distilled ethanol are now placed in a 10 ml Schlenk vessel with a magnetic stirrer and this is exposed six times to a sequence of application of a high vacuum and letting down with argon. The solution is cooled to 0 °C with the aid of an ice bath and 70 //I (1.07 mmol) of methanesulfonic acid are then cautiously added. [Rh(nbd)2] BF4 (3.2 mg; 0.0086 mmol) and (S)-Solphos (ligand A, 6.0 mg; 0.0090 mmol) are added to a further 10 ml Schlenk vessel placed under argon by the above process and are dissolved in 5 ml of ethanol. The two solutions are stirred at RTfor 10 min and then transferred into the autoes bj m?if ff fflmif |nj j p,|0 |0m Qf Qp y^ Qi[|Qf |j ||fl M hydrogen gas (10 bar, four times) and hydrogen gas is finally forced in under 10 bar. The temperature is kept at 25 °C and stirring is started. After a reaction time of G7.5 h, the pressure is let down to normal pressure. A clear solution is obtained. The product is concentrated to dryness by means of a rotary evaporator at a bath temperature of about 40 °C. The purity is determined as 94.1 % by means of GC and the diastereomeric ratio of II i m i nil ii i D ttiii ID 3ii: u u. ODCICII 11.1:1. Example B2: The results of Example B1 and further experiments carried out analogously to the process according to Example B1 are summarized in the following Table 1. Ligands: The structures of the ligands used are shown in the following: Note: Only little is known of the hydrogenation of homo-allylic amines. Astonishingly, however, it is possible to prepare the two diastereomers (2R, 3R)- [3-(3-methoxy-phenyl)-2-methyl-pentyl]- dimethyl-amine and (2R, 3S)-[3-(3-methoxy-phenyl)-2-methyl-pentyl]-dim^Y|-arnin§ selectively in a high yleld and optical purity with the homogeneous catalysis by varylng the catalyst. As a rule, the use of purified starting substance is advantageous for successful highly selective hydrogenation. For this, the mixture of (Z)-(2R)-[3-(3-methoxy-phenyl)-2-methyl- pent-3-enyl]-dimethyl-amine, (£)-(2R)-[3-(3-methoxy-phenyl)-2-methyl-pent-3-enyl]-dimethyl- amine and further unknown by-products which is obtained from the elimination is subjected to a hydrochloride precipitation. in ttio OQOG of nydroQcnation of (Z)«(2^)43-(^-mQtno^-Dn0ny))-2-w&thy]-^rtt-9-eny]]- dimethyl-amine with a homogeneous rhodium catalyst containing the ligand (S)-A, a purity of 94.1 % and a diastereomeric ratio of the {2R.3R) to the {2R,3S) compound of 11.1:1 is achieved. Astonishingly, the hydrogenation with a rhodium catalyst which contains the other enantiomer of the ligand A, namely {R)-A, also give almost the same diastereomeric ratios as with the ligand (S)-A. It can therefore be assumed that a catalyst with the racemic ligand also produces good results, which is a considerable economic advantage. If the ligand H is employed, the other diastereomer, the (2R,3S) compound is obtained with a purity of about 97 % and a diastereomeric ratio of 29:1 (97 %). 1. Process for the preparation of at least one substituted dimethyl-{3-aryl-butyl)-amine compound of the general formula III wherein R1, R1', R2. R3 independently of one another each denote -H or -C1-5-alkyl, R4, R4', R5, R5', R6 are identical or different and each represent -H, -OH, -C1-4-alkyl, -O-CM- alkyl, partly fluorinated or perfluorinated -C1-4-aikyl, partly fluorinated or perfluorinated -O-CM-alkyl, -O-(CHa)n-phenyl where n is 1,2 or 3. F, CI or OR8, or two adjacent radicals R4 and Rs, Rs and R6, R8 and R** or R5' and R4* represent a group -OCH=CHO-, -CH=C(RBK>-, -CH=C{R9)-S- or -CH=CH-C(OR10)=CH- a3 part of a ring, with the proviso that the other particular radicals R6, R5 and R4', R4, R5' and Rs', R4, R* and R4' or R4, Rs and R8 have the abovementioned meaning, R8 denotes -CO-C^-alkyl, -PO(0-C,-,-alkyl)2, -CO-CjKU-R", -^(O-d^-alkyl), -CO-CHR"-NHR1s. -CO-NH-C6H3-(RM)2 or an unsubstityted or substituted pyrWyl, thlenyl, thiazolyl or phenyf group, R* denotes -H or -GM-alkyl, R10 denotes -H or -CM-alkyl, R" -OC(0)-Ci4-alkyl in the ortho-position or -CHrN-(Rls)2 In the meta- or para-position, wherein R" in each case -Cw-alkyl or the two radicals R's together with the bridging nitrogen atom form a 4-morpholino radical, R12 and R1 J are identical or different and each represent «H, -C^-alkyl or -C3rcycloalkyl, or R" and R" together denote -(CH2)M- as part of a ring, R" -H, -OH, -d-ralkyl, partly fluorinated or perfluorinated -Cratkyl, -O.Cw-alky(, -phenyl, -Oaryl, -F or-CI, with the proviso that the radicals R14 are identical or different, in each case in the form of one of their pure stereoisomers, in particular enantiomers or diastereomers, their racemates or in the form of a mixture of stereoisomers, in particular the enantiomers or diastereomers, in any desired mixing ratio, optionally in the form of a salt, a solvate or in the form of a salt and solvate, characterized in that a substituted dlmethyl- general formula II wherein the radicals R\ R1', R2, R3, R4, R4', Rs, R* and R6 each have the abovementioned meaning, in each case in the form of racemates, pure enantiomers, mixtures of enantiomers in any desired mixing ratio, Z or E isomers or mixtures of Z or E Isomers in any desired mixing ratio, salts or solvates, is reacted in the presence of hydrogen and a soluble rhodium salt or rhodium complex, as a homogeneous catalyst, to give a compound of the general formula III, wherein the rhodium salts or rhodium complexes used as the catalyst contain chiral ligands with two secondary phosphine groups (diphosphine ligand). 2. Process according to claim 1, characterized in that the compound of the formula II is one of the formula IIA wherein R1 is -C-s-alkyl. R! denotes -Hor -Cs-alkyl, R3 denotes -H or -Cs-alkyt, R4 is -H, -OH. -C^-alkyl. -O-C^-alkyl, -O-benzyl. -CFa. -Q-CF3, -CI, -F or -OR8. Rs Is -H, -OH, -CM-alkyl. -O-CM-alkyl. -O-benzyl. -CHF2, -CFS, -O-CFj, -CI, -F or -OR6. R8 denotes -H. -OH, -C,^-alkyl, -O-CM-alkyl. -Q-benzyl. -CF3, -O-CFs. -CI. -F or -OR*, with the proviso that two of the radicals R4, Rs or R* are -H, or R4 and R$ together denote a group -CH=C(R*)-O- or -CH=C(R*)-S- as part of a ring, with the proviso that R* is -H, or R8 and R* together denote a group -CH=CH-C(OR'°)=CH- as part of a ring, with the proviso that R4 is -H, and R8 denotes -CO-Cs-alkyl. -PO(0-CM-aIkyl)j. -CO-C^-R11, -CO(0-C14-aikyl), -CO-CHR'*-NHR13. -CO-NH-CsH3-(R14)2 or an unsubstituted or substituted pyridyl, thienyl, thiazolyl or phenyl group, R9 denotes -H or -Ci^-alkyl. R10 denotes -H or Ct.a-alkyl, R" denotes -OCfOH^-alkyl in the ortho-position or -CHrN-(R1s)a in the meta- or para- position, wherein R1S is -CM-alkyl or the two radicals R1S together with the bridging nitrogen atom form a 4-morpholino radical, R1* and R13 are identical or different and each represent -H, -C^-alkyl or -Cj^-cycloalkyl, or R" and R" together denote -(CH^ as part of a ring, R14 denotes -H. -OH. -CLT-alkyl, -O-Qw-alkyl, -phenyl, *0-aryl, -CF3, -CI or-F, with the proviso that the two radicals R14 are identical or different. 3. Process according to claim 2, characterized in that in formula IIA R1 denotes -d.3-alkyl, R2 denotes -H or C,.3-alkyl, R3 denotes -H or C^aUcyl, R4 denotes -H, -OH, -CI, -F or -OR", Rs denotes -H, -OH, -CM-alkyl, -O-CM-alkylr -O-benzyl, -CHF2, -CF3, -CI, -F or -OR8, R8 denotes -H, -OH, -O- Ci^-alkyl, -O-benzyl, -CF3, -CI, -F or -OR8, with the proviso that two of the radicals R4, Rs or R8 are -H, or R4 and Rs together denote a group -CH=C(R9)-O- or -CH=C(R9j-S- as part of a ring, with the proviso that R* Is -H, or RS and R6 together denote a group -CH=CH-C(ORw)=CH- as part of a ring, with the proviso that R4 is -H, and R8 to R10 have the meanings given in claim 2. 4. Process according to claim 3, characterized in that in formula HA rVis-CHjOr-CjHr, RMs-H,-CHjor-CHjCH3l R3is-H,-CH3or-CH?CH3, fVis-Hor-OH, Rs is -H, -OH, -OCH,. -CHFj or -OR8. R8fs-H,-OHor-CF3l with the proviso that two radicals R\ R? or R8 are -H, or R* and Rs together represent a group -CH=C(CH3)-S- as part of a ring, with the proviso that R* is -H, or R5 and Re together denote -CH=CH-C(OH)=CH- as part of a ring, with the proviso that R* is -H, R8 denotes -CO-CaKU-R1' and R11 denotes -OC(0)-C,.ralkyl in the ortho-position. 5. Process according to claim 4, characterized in that in formula IIA, R1 and R3 each represent -CH3 and Rs represents -OCH3 and the remaining radicals represent a hydrogen atom, corresponding to the compound of the formula IIB: are employed in the form of mixtures of its stereoisomers or in the form of a specific, isolated stereoisomer. 6. Process according to claim 5, characterized In that the compound of the formula IIB is (Z> (2R)-3-((3-methoxy-phenyl)-2-methyl-pent-3-enyl]-dimethylamine. 7. Process according to claim 6, characterized in that the compound of the formula III is the diastereomers {2R,3R)- and (2S,3RH3-(3^^°^i>neny'^metny,"PentyO"dime*y'^rnine" wherein the diastereomeric ratio is greater than or equal to 70:30 in favour of one of the two diastereomers. 8. Process according to claim 1, characterized in that the ligand corresponds to the formula secondary phosphine-skeleton-secondary phosphine, the ligand forms a five- to ten^ membered ring with the metal atom, and the skeleton contains 2 to 30 G atoms end optionally hetero atoms O, S, NH and/or N-d-C4-alkyl. 9. Process according to claim 8, characterized in that the skeleton is bivalent radicals of atkanes, heteroatkanes, alkenes, cycioalkanes, cycloatkenes, haterocycloalkanes, heterocycloalkenes, bicycloalkanes, bicycloheteroalkanes, spirobiscycloalkanes, spirobiscycloheteroalkanes, arylenes, heteroarylenes, bisarylenes, bisheteroarylenes, metallocenes, preferably ferrocene, and the radical is unsubstituted or substituted by Ct-Cs-alkyl, Ci-Ca-alkoxy, Ct-C6-alkylthio, C benzyloxy, phenylthio, benzylthio, halogen, OH, tr^d-Ce-alkylJsilyl, secondary amino, -COjH, -S03H, -C02R\ -SO3R', -O-CfOJ-R1, -NH-C(0)R\ -O-SCb-R', and -NH-SOjR'. wherein R' represents d-C6-alky|, C«-C6-cycloalkyl. phenyl or benzyl. 10. Process according to claim 1, characterized in that the secondary phosphine groups contain identical or different hydrocarbon radicals as substltuents, and the two secondary phosphine groups in the diphosphine ligands are identical or different. 11. Process according to claim 1, characterized in that the diphosphine ligands are those of the formulae A to I wherein: Xt and X2 independently of one another denote a secondary phosphine, wherein the phosphlne group two identical or different radicals chosen from the group of linear or branched C1-Cu-alkyl; Cs-Cl2-cycloalkyl or C6-C,rcycloalkyl-CH2- which is unsubstituted or substituted by C1-Cs-alkyl or (VC»-alkoxy; phenyl, naphthyl, furyl or benzyl; or phenyl or benzyl which is substituted by halogen, C1-Ce-alkyl, trifluoromethyl. d-CValkoxy, trifluoromethoxy, (QHsfeSi, (C,-Ct2-alkyl)aSi or secondary amino, R denotes CrC^alkyl, preferably methyl, C6-Cio-aryl, or Cy-C^ralkyl, and X3 and >C independently of one another denote H, OH, C^-alky!, Ci-C4-aIkoxy, benzyloxy, -CH(C,-C 12. Process according to claim 11, characterized in that a compound of the formula IIC.1 is employed, the diphosphine ligand is chosen from a compound of the formulae A to F according to claim 11, and thediastereomer(2R,3RH3-{3-methoxy-phenyl)-2-methyl-pBn(yl]- dimethyl-amine is predominantly obtained as the compound of the formula III, wherein the diastereomeric ratio (2R,3R):(2S,3R) Is greater than or equal to 75:25. 13. Process according to claim 11, characterized In that a compound of the formula IIC.1 is employed, the dlphosphine ligand is chosen from a compound of the formulae G, H or I according to claim 11, and the diastereomer (2S,3R)-[3-(3-methoxy-phenyl)-2-methyl-pentyl]- dimethyl-amine is predominantly obtained as the compound of the formula III, wherein the diastereomeric ratio (2S,3R):(2R,3R) is greater than or equal to 75:25. ABSTRACT Title : PROCESS FOR THE PREPARATION OF SUBSTITUTED DIMETHYL-(3-ARYL-BUTYL)-AMINE COMPOUNDS BY MEAN OF HOMOGENEOUS CATALYSIS Compounds of the formula(II) can be hydrogenated to the corresponding butane derivatives in the presence of homogeneous catalysts comprising metal salts or complexes containing metals from the group consisting of Rh, Ir and Ru and preferably containing diphosphine ligands, with, in addition, excellent optical yields being achieved when one of R2 and R3 is not an H atom and the diphosphine ligand is chiral.

Documents:

02197-kolnp-2008-abstract.pdf

02197-kolnp-2008-claims.pdf

02197-kolnp-2008-correspondence others.pdf

02197-kolnp-2008-description complete.pdf

02197-kolnp-2008-form 1.pdf

02197-kolnp-2008-form 2.pdf

02197-kolnp-2008-form 3.pdf

02197-kolnp-2008-form 5.pdf

02197-kolnp-2008-international publication.pdf

02197-kolnp-2008-international search report.pdf

02197-kolnp-2008-pct request form.pdf

02197-kolnp-2008-translated copy of priority document.pdf

2197-KOLNP-2008-(05-04-2013)-ABSTRACT.pdf

2197-KOLNP-2008-(05-04-2013)-CLAIMS.pdf

2197-KOLNP-2008-(05-04-2013)-CORRESPONDENCE.pdf

2197-KOLNP-2008-(05-04-2013)-DESCRIPTION (COMPLETE).pdf

2197-KOLNP-2008-(05-04-2013)-FORM 1.pdf

2197-KOLNP-2008-(05-04-2013)-FORM 2.pdf

2197-KOLNP-2008-(05-04-2013)-FORM 3.pdf

2197-KOLNP-2008-(05-04-2013)-OTHERS.pdf

2197-KOLNP-2008-(23-07-2012)-ANNEXURE TO FORM 3.pdf

2197-KOLNP-2008-(23-07-2012)-EXAMINATION REPORT REPLY RECEIVED.pdf

2197-KOLNP-2008-CORRESPONDENCE OTHERS 1.1.pdf

2197-KOLNP-2008-CORRESPONDENCE-1.2.pdf

2197-KOLNP-2008-CORRESPONDENCE.pdf

2197-KOLNP-2008-EXAMINATION REPORT.pdf

2197-KOLNP-2008-FORM 18-1.1.pdf

2197-KOLNP-2008-FORM 18.pdf

2197-KOLNP-2008-FORM 26-1.1.pdf

2197-KOLNP-2008-FORM 26.pdf

2197-KOLNP-2008-GRANTED-ABSTRACT.pdf

2197-KOLNP-2008-GRANTED-CLAIMS.pdf

2197-KOLNP-2008-GRANTED-DESCRIPTION (COMPLETE).pdf

2197-KOLNP-2008-GRANTED-FORM 1.pdf

2197-KOLNP-2008-GRANTED-FORM 2.pdf

2197-KOLNP-2008-GRANTED-FORM 3.pdf

2197-KOLNP-2008-GRANTED-FORM 5.pdf

2197-KOLNP-2008-GRANTED-SPECIFICATION-COMPLETE.pdf

2197-KOLNP-2008-INTERNATIONAL PRELIMINARY REPORT.pdf

2197-KOLNP-2008-INTERNATIONAL PUBLICATION.pdf

2197-KOLNP-2008-INTERNATIONAL SEARCH AUTHORITY REPORT 1.1.pdf

2197-KOLNP-2008-INTERNATIONAL SEARCH REPORT & OTHERS.pdf

2197-KOLNP-2008-PETITION UNDER RULE 12.pdf

2197-KOLNP-2008-REPLY TO EXAMINATION REPORT.pdf

2197-KOLNP-2008-TRANSLATED COPY OF PRIORITY DOCUMENT.pdf

abstract-02197-kolnp-2008.jpg